ESR2 and breast carcinoma: The most studied molecular targets in breast cancer drug discovery included epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor‐2 (VEGFR‐2), cyclin‐dependent kinases (CDKs), tubulin, and hormone receptors (ERα and ERβ) (Table 4).